Global Alzheimer's Disease Drug Market Growth 2025-2031

The global Alzheimer's Disease Drug market size is predicted to grow from US$ 3645 million in 2025 to US$ 3999 million in 2031; it is expected to grow at a CAGR of 1.6% from 2025 to 2031.

Alzheimer"s disease (AD), also referred to simply as Alzheimer"s, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.

The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.

LP Information, Inc. (LPI) ' newest research report, the “Alzheimer's Disease Drug Industry Forecast” looks at past sales and reviews total world Alzheimer's Disease Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Alzheimer's Disease Drug sales for 2025 through 2031. With Alzheimer's Disease Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Alzheimer's Disease Drug industry.

This Insight Report provides a comprehensive analysis of the global Alzheimer's Disease Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Alzheimer's Disease Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Alzheimer's Disease Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alzheimer's Disease Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alzheimer's Disease Drug.

This report presents a comprehensive overview, market shares, and growth opportunities of Alzheimer's Disease Drug market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Donepezil
Memantine
Rivastigmine
Others

Segmentation by Application:
Early to Moderate Stages
Moderate to Severe Stages

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck

Key Questions Addressed in this Report

What is the 10-year outlook for the global Alzheimer's Disease Drug market?

What factors are driving Alzheimer's Disease Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Alzheimer's Disease Drug market opportunities vary by end market size?

How does Alzheimer's Disease Drug break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.